Xap Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$17.9M
- Investors
-
3
Xap Therapeutics General Information
Description
Developer of a synthetic biology-driven platform designed for cell therapeutics based in Cambridge. The company's platform applies clustered regularly interspaced short palindromic repeats technology to engineer induced pluripotent stem cells to form the basis of a cell platform producing a "chassis" cell, which is functionalized into cell therapies by genetically engineered constructs, enabling doctors to improve treatment of serious diseases, including autoimmunity and cancer.
Contact Information
Website
www.xaptherapeutics.comCorporate Office
- Babraham Research Campus
- Maia Building B270
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Babraham Research Campus
- Maia Building B270
- Cambridge CB22 3AT
- England, United Kingdom
Xap Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 19-Apr-2021 | $17.9M | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup |
Xap Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Preferred |
Xap Therapeutics Patents
Xap Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024316815-A1 | Compositions comprising gpcr based chimeric antigen receptor and methods of use | Pending | 02-Aug-2023 | ||
| EP-4754124-A1 | Compositions comprising gpcr based chimeric antigen receptor and methods of use | Pending | 02-Aug-2023 | ||
| WO-2025027344-A1 | Compositions comprising gpcr based chimeric antigen receptor and methods of use | Inactive | 02-Aug-2023 | ||
| GB-202311858-D0 | Methods and compositions | Inactive | 02-Aug-2023 | ||
| AU-2022294190-A1 | Methods and compositions | Pending | 16-Jun-2021 | C07K14/705 |
Xap Therapeutics Signals
Xap Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amplitude Ventures | Venture Capital | Minority | ||
| SR One | Corporate Venture Capital | Minority | ||
| Frame Shift Bio-Incubator | Accelerator/Incubator |
Xap Therapeutics FAQs
-
When was Xap Therapeutics founded?
Xap Therapeutics was founded in 2017.
-
Where is Xap Therapeutics headquartered?
Xap Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Xap Therapeutics?
Xap Therapeutics has 25 total employees.
-
What industry is Xap Therapeutics in?
Xap Therapeutics’s primary industry is Drug Delivery.
-
Is Xap Therapeutics a private or public company?
Xap Therapeutics is a Private company.
-
What is the current valuation of Xap Therapeutics?
The current valuation of Xap Therapeutics is .
-
What is Xap Therapeutics’s current revenue?
The current revenue for Xap Therapeutics is .
-
How much funding has Xap Therapeutics raised over time?
Xap Therapeutics has raised $17.9M.
-
Who are Xap Therapeutics’s investors?
Amplitude Ventures, SR One, and Frame Shift Bio-Incubator have invested in Xap Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process